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Abstract
Immunogen design for HIV-1 vaccines could be based on epitope identification of naturally occurring neutralizing
antibodies in infected patients. A tier 2 neutralizing monoclonal antibody (mAb), HJ16 recognizes a new epitope in the CD4
binding site (CD4bs) region that only partially overlaps with the b12 epitope. We aimed to identify the critical binding site
by resistance induction in a sensitive primary CRF02_AG strain. In four independent dose-escalation studies, the N276D
mutation was consistently the only alteration found and it was confirmed to be responsible for resistance to HJ16 by site-
directed mutagenesis in envelopes (envs) of the homologous CRF02_AG, as well as of a subtype A and a subtype C primary
isolate. This mutation removes an N-linked glycosylation site. The effect of N276D was very selective, as it failed to confer
resistance to a range of other entry inhibitors. Remarkably, sensitivity to the CD4bs VRC01 and VRC03 mAbs was increased
in the N276D mutated viruses. These data indicate that binding of the CD4bs specific HJ16 mAb critically depends on the
interaction with the N276-glycan, thus indicating that HJ16 is the first glycan dependent CD4bs-specific mAb.
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Introduction
Designing a protective HIV-1 vaccine remains as much of a
challenge today as in the 1980s. The envelope has been a main
target in HIV-1 vaccine development since interaction of
particular sites of HIV-1 envelope (Env) with cellular receptors is
essential to mediate viral entry into human target cells. However,
Env imposes a range of obstacles to vaccine development such as
the presence of immunodominant non-neutralizing epitopes, high
variability of neutralization-sensitive regions and their shielding by
glycans. In addition, the flexibility of Env and its ability to undergo
conformational changes during the process of cell entry severely
limit the window of opportunity during which antibodies (Abs) can
be effective [1].
Until recently, only a limited number of cross-neutralizing
monoclonal Abs (mAbs) were characterized, including some that
target the CD4 binding site (CD4bs), such as b12 and F105, but
more recently a wealth of promising new very broadly neutralizing
Abs were discovered e.g. Wu and Zhou described the CD4bs-
specific VRC01 and VRC03 mAbs and Falkowska described
PGV04. In addition, Walker et al. isolated PG9 & PG16 mAbs,
recognizing, V1/V2 glycans, but also the PGT series, which was
found to compete with the prototypical glycan binding 2G12 mAb
[1–6].
We obtained a neutralizing mAb referred to as HJ16 from an
African women in our HIV-1 cohort at the Institute of Tropical
Medicine (ITM). It competed with CD4 for binding to gp120, but
its neutralization spectrum was clearly different from b12, as it was
mainly effective against tier 2 strains (which comprises the majority
of primary HIV-1 isolates), whereas b12 rather neutralizes tier 1
strains [7,8].
Our objective in the present study was to identify critical site(s)
within the HJ16 epitope by resistance induction in a primary
CRF02_AG strain that was very sensitive to HJ16 neutralization
in a primary PBMC based neutralization assay.
Materials and Methods
Ethics Statement
This study was approved by the Institutional Review Board of
ITM and the Ethical Committee of the University Hospital of
Antwerp. All participants understood and signed an informed
consent.
Entry Inhibitors Used
The CD4bs specific HJ16 mAb was produced by one of the co-
authors (Dr. Davide Corti). Other CD4bs targeting reagents
include the broad neutralizing mAbs b12 and PVG04 obtained
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from Dr. Dennis Burton (Scripps Institute, La Jolla, CA USA),
VRC01 and VRCO3 from Dr. John Mascola (Vaccine Research
Centre NIH, Bethesda, MD USA), the llama heavy chain
antibody (VHH) A12 from Dr. Theo Verrips (University of
Utrecht, Utrecht, The Netherlands) [9], the CD4 miniprotein
M48-U1 from Dr. Loic Martin (Centre a` l’Energie Atomique,
Saclay, France) [10] and soluble CD4 (sCD4), which was
purchased from Progenics Pharmaceuticals, New York, USA. In
addition we obtained the mAb 2F5 and 2G12 from Dr. Hermann
Katinger (Polymun, Vienna, Austria) and the VHH 1B5 from Dr.
Theo Verrips [11]. The CCR5 inhibitor Maraviroc was obtained
from the NIH AIDS Research and Reference Reagent Program,
Germantown, MD USA.
Cells
Buffy coats from healthy donors were obtained from the Red
Cross Blood Transfusion Center at the University Hospital of
Antwerp and were used for isolation of peripheral blood
mononuclear cells (PBMC) by LymfoPrep (Axis-Shield, Oslo,
Norway). These PBMC were adjusted to 16106/ml in complete
culture medium, consisting of RPMI 1640, 15% fetal calf serum
(FCS), 0.03% L-glutamine and 50 mg/ml gentamycin (Lonza,
Verviers, Belgium) and 2 mg/ml polybrene (Sigma-Aldrich,
Bornem, Belgium). Cells were stimulated with 0.5 mg/ml phyto-
hemagglutinin (PHA, Oxoid, Hampshire, UK) for 2 days and 1
day with 200 U/ml interleukin-2 (IL-2, Gentaur, Brussels,
Belgium) in a 7% CO2 incubator at 37uC and then used for
neutralization assays.
The following cell lines were obtained from the NIH AIDS
Research and Reference Reagent Program: TZMbl (cat no. 8129);
HOS.CD4-R5 (cat no. 3318) and GHOST(3)X4/R5 (cat no.
3943). The HEK 293T cells (CRL-11268) were obtained from the
American Type Culture Collection (ATCC, Manassas, Virginia,
USA).
Replication Competent HIV-1 Infectious Virus (IV) and
Single-cycle HIV-1 Pseudoviruses (PV)
The VI1090 CRF02_AG strain was isolated in a classical
PBMC culture from a 38 year old heterosexual Nigerian man. The
env gene was amplified from PBMC cultures followed by cloning
into the pcDNA4/TO expression vector [12]. Additional PV
constructs, derived from a primary clade C virus VI829 [13] and
from a near full length subtype A clone 92RW009.6 (NIH4006)
[14], were also included. PV were generated in a 24-well plate by
transfection of HEK 293T cells with pNL4-3.LucR2E2, obtained
from NIH AIDS Research and Reference reagent program and
the env containing plasmid, as previously described [12].
Sequencing of the PV constructs and phylogenetic analysis of
the complete gp160 confirmed identity between the envs of the
pseudoviruses and the original replicating viruses VI1090, VI829
and 92RW009.6 respectively. The full length env sequence of the
VI1090 PV construct has been deposited with GenBank (accession
number HQ912710).
Mutagenesis
Site-directed mutagenesis was carried out on the PV constructs
(VI1090, VI829 and 92RW009.6) using the QuikChange Light-
ning Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA,
USA) following the guidelines of the manufacturer. Primers used
to introduce the desired mutation were: VI1090_276D_Fwd (59-G
GTA GTG ATT AGA TCT GAA GAT ATC ACA AAC AAT
GCC AAA -39) and VI1090_276D_Rev (59-TTT GGC ATT
GTT TGT GAT ATC TTC AGA TCT AAT CAC TAC C -39);
VI829_276D_Fwd (59-GAG ATA ATA ATT AGA TCT GAA
GAT ATA ACA GAT AAT GTC AAA AC -39) and
VI829_276D_Rev (59-GT TTT GAC ATT ATC TGT TAT
ATC TTC AGA TCT AAT TAT TAT CTC -39);
92RW009_276D_Fwd (59-G ATA ATA ATT AGA TCT GAA
GAT ATT ACA AAC AAT GCC AAA ACC -39) and
92RW009_276D_Rev (59-GGT TTT GGC ATT GTT TGT
AAT ATC TTC AGA TCT AAT TAT TAT C 39). Underlined
and in bold the mutated N276 D. The presence of the mutation
was confirmed by sequencing the complete env gp160.
Neutralization Assays
Extended incubation PBMC-based assay: This assay has been
previously described [15,16]. Briefly, the virus stock was diluted
in a fivefold series from 1/2 to 1/6250 in culture medium (RPMI-
1640 medium supplemented with 15% FCS and 200 U/ml IL-2).
Ninety ml of each virus dilution were mixed with 5 ml of plasma
+5 ml of culture medium (final plasma concentration 1/20) or 5 mg
mAb +5 ml IgG-depleted HIV-negative plasma (IgG was removed
with a Protein G column [17]) to give a final mAb concentration of
50 mg/ml. As a negative control, either HIV seronegative plasma
(pooled from 100 healthy donors) or purified IgG thereof were
used for incubation with the virus dilution. After an incubation
phase of 24 hours, 20 ml of each plasma/virus or mAb/virus
mixture were first dispensed in quadruplicate into flat bottom 96-
Table 1. Neutralization profile of HJ patient plasma and HJ16
mAb in the 24 h/1 h/14da extended incubation PBMC assay.
Subtype Strain HJ plasma HJ16 mAb
1/20 dilutionb 50 ug/mlb
A VI191 96c 66
92RW009.6 Ec 96
CA1 99 E
B SF162 99 0
MN E E
BaL 98 66
89.6 91 55
C VI829 86 91
VI882 99 E
VI1358 95 41
92Br025 98 78
D VI824 78 55
CI13 99 80
CRF01_AE VI1888 89 22
CRF02_AG VI1090 95 99
VI2680 0,0 37
CI20 93 71
CA18 97 80
VI1380 0,0 95
VI2727 84 E
aIn this assay virus and plasma or mAb are incubated during 24 hours, followed
by an absorption time of 1 hour during which the mAb/virus mixture is co-
incubated with donor PBMC. After washing the PBMC cultures are maintained
for 14 days.
b% Neutralization obtained with 1:20 plasma dilution or 50 mg/ml mAb during
the incubation phase.
c$80% reduction in virus titer is highlighted, E = enhancement of infection.
doi:10.1371/journal.pone.0068863.t001
Resistance to CD4 Binding Site Specific HJ16 mAb
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well microplates and 75,000 PBMC in 100 ml culture medium
were added to each well. Plates were then left in a CO2 incubator
at 37uC during the absorption phase of 1 hour. Afterwards, cells
were washed three times by centrifugation at 2000 rpm for 10
minutes, the supernatant was aspirated and 180 ml fresh culture
medium was added to each well. After 14 days of incubation in a
CO2 incubator, 200 ml of the supernatant were mixed with 50 ml
Nonidet P40 (0.25% in PBS; Fluka, Sigma-Aldrich, Puurs,
Belgium) to disrupt virions and this mixture was analyzed in our
in house HIV p24 antigen assay [17]. Wells with an OD.0.3 were
considered to be positive.
Virus titers were calculated by the method of Reed and Muench
[18]. Neutralization activities are presented as the percentage
reduction in infectious titer following incubation with plasma from
the patient or mAb relative to its titer following incubation with
control HIV seronegative pooled plasma or purified IgG from this
pool respectively. An 80% reduction in titer was considered
significant. Neutralization indices were translated into % neutral-
ization by using the formula: 100-POWER(10;2-neutralization
index). A detailed protocol can be found at http://www.europrise.
org/documents/NEUTNET/SOPS/6B_ITG_PBMC.pdf.
Cell line based assays: Neutralization capacity of HJ patient plasma
and HJ16 mAb was measured against a fixed dose of infectious
virus (IV) or pseudotyped virus (PV) on TZMbl, whereas PV only
was used in HOS cells and the related GHOST cells [19,20]. After
48 h of incubating cells, virus and plasma or Ab, luciferase
reporter gene production was quantified upon cell lysis and
addition of firefly luciferase substrate (Perkin-Elmer, Waltham,
Massachusetts USA). Emitted relative light units (RLUs) were
quantified on a LB 941 BertholdH luminometer (Bad Wildbad,
Germany). SteadyLiteH was used as a substrate in the TZMbl
assay and BriteLiteH in the GHOST and HOS assay (both are
from Perkin-Elmer). The fixed dose of virus to be used was
determined in a preliminary titration experiment, wherein 16104
TZMbl, HOS or GHOST cells were infected with a range of viral
dilutions in a total volume of 200 ml to establish the dose, which
resulted in a signal of 50,000 to 100,000 RLU. Background RLUs
(only cells, no virus) for TZMbl, HOS and GHOST were ,4,000,
40 and 50 respectively. In the TZMbl assay diethylaminoethyl-
dextran (DEAE-dextran, Sigma, Belgium) was used at 15 mg/ml
final concentration to enhance virus infectivity. In the actual
neutralization experiments, Abs or plasma were pre-incubated with
pseudoviruses for 1 h at 37uC. The Ab concentration or plasma
dilution causing a 50% reduction in luciferase reporter gene production
was determined by linear regression analysis in Microsoft Office Excel
as described on http://www.hiv.lanl.gov/content/nab-reference-
strains/html/Protocol-for-Neutralizing-Antibody-Screening-Assay-for-
HIV-1-in-TZM-bl-Cells-November-2010.pdf. The HIV-seronegative
plasma pool and purified IgG, already described in the PBMC assay,
were used as negative controls in cell line based assays.
Structural Analyses
The crystal structure coordinates of the different gp120
molecules interacting with sCD4 (pdb 1gc1) or the human
CD4bs-specific antibodies PGV04 (pdb 3se9), b12 (pdb 3dnl)
and VRC01 (pdb 3ngb) were used to identify the footprint of
interaction of each ligand on gp120 within an interaction distance
of 5 Au. The solved gp120-bound glycans and their atomic
coordinates were highlighted as described in the deposited pdb file.
The details of hydrogen bonds between Tyr-28 and Ser-30 of the
VRC01 light chain and the protein-proximal N276-acetylgluco-
samine (as described in [3]) were determined as polar contacts
between the two light chain residues and the neighboring residues.
Figures were made with Mac PyMOL.
Results
Neutralization Breadth of HJ16 and Selection of a
Sensitive Isolate to Induce Resistance
The HJ16 mAb was isolated from memory B cells of an HIV-1
subtype C infected Congolese woman (identified HJ), whose
plasma showed an exceptionally broad neutralizing profile
(neutralizing 15 out of 20 strains tested) upon screening in the
‘‘extended incubation’’ PBMC assay (Table 1). In the same assay,
the HJ16 mAb neutralized six strains. Of these 4 were also
neutralized by the plasma but two strains (92RW009.6 and
VI1380) were not, indicating that the neutralizing capacity of the
plasma is not recapitulated by this single mAb. Clearly, the
CRF02_AG strain VI1090 was very susceptible to neutralization
by both the original plasma and the HJ16 mAb.
In a previous study we have shown that the neutralization
capacity of patient sera, as well as that of individual mAbs is highly
dependent on the type of assay used [8]. Exploring the activity of
HJ16 against VI1090 in other types of neutralization assays using
PBMC or cell lines as target cells, in combination with primary
replicating infectious virus (IV) or non-replicating pseudovirus
(PV) confirmed sensitivity of VI1090 to 50 mg/ml HJ16 in all
cases, whereas a 1/20 dilution of the corresponding HJ plasma
showed a weaker activity (Table 2). A further titration indicated
that 0.15 mg/ml of HJ16 neutralized VI1090 at a 50% level in the
TZMbl assay.
In conclusion, the VI1090 virus is very sensitive to neutraliza-
tion by HJ16, irrespective the assay used and was therefore
selected for resistance induction.
Resistance Induction in VI1090 with HJ16 Results in a
Unique N276D Mutation
The primary VI1090 strain was cultured in activated donor
PBMC in the presence of increasing concentrations of HJ16,
starting at 0.10 mg/ml ( = just below the IC50 in TZMbl). After
each week, p24 ELISA was performed and positive cultures were
passaged again with a 2–5 fold increased concentration of HJ16.
After 35 days, we obtained a virus growing in the presence of
187.5 mg/ml HJ16 (,2,000 fold increase). This procedure was
reproduced in four independent experiments. Table 3 shows that
in each case a similar high-level resistance against HJ16 was
obtained, whereas the sensitivity towards TriMab remained
unchanged. TriMab is a combination of 2F5 (targeting the
membrane proximal part of gp41), 2G12 (recognizing a specific
Table 2. Neutralization profile of HJ patient plasma and HJ16
mAb against VI1090 virus in various assays.
PBMC
baseda Cell line based
b
TZMbl_IV TZMbl_PV GHOST_PV HOS_PV
HJ plasmac 95e 42f 48f 43f 61f
HJ16 mAbd 99e 97f 100f 100f 100f
aThe extended incubation PBMC assay was performed with the infectious virus
VI1090.
bBoth infectious virus (IV) and pseudovirus (PV) were used in the TZMbl assay,
whereas only PV was used in the GHOST and HOS assays.
cHJ plasma used at 1:20.
dmAb used at 50 mg/ml.
e% Reduction in virus titer.
f% Reduction in luciferase activity.
doi:10.1371/journal.pone.0068863.t002
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configuration of glycans at positions N295, N332, N339, N386
and N392 on gp120) and b12 (prototypical CD4bs mAb) [1].
Sequencing revealed the presence of a single point mutation in
all four HJ16 resistant variants whereby the neutral asparagine (N)
was replaced by the negatively charged aspartic acid (D) at
position 276 (numbering according to HxB2), resulting in the loss
of a potential N linked glycosylation site (PNGS) [21]. Searching
the Los Alamos database indicated that this N276D point
mutation is only seen in 0.85% (19/2247) of group M isolates.
Sequences of the four HJ16 resistant VI1090 viruses as well as the
control viruses, grown in absence of HJ16, have been deposited at
GenBank (accession numbers KC980915-KC980920).
The N276D Mutations Confers Selective Resistance to
HJ16 across Subtypes
In order to ascertain that this rare mutation was indeed
responsible for resistance to HJ16, N276D site-directed mutants
were generated in the envs of three sensitive strains from different
subtypes, selected from Table 1: the original VI1090
(CRF02_AG), 92RW009.6 (subtype A) and VI829 (subtype C).
Next, the impact of N276D on the sensitivity to HJ16 and other
CD4bs mAbs (b12, VRC01 and VRC03) [1], two llama single
heavy chain antibodies or VHHs (A12 and 1B5) [9,11]; the CD4
‘‘miniprotein’’ M48-U1 [10] and soluble CD4 was assessed in the
TZMbl neutralization assay. In addition, the TriMab combination
and the CCR5 inhibitor Maraviroc were used.
Clearly N276D mutation produced high-level resistance specif-
ically to HJ16 in all three isolates (Table 4). There was no evidence
of cross-resistance of the N276D mutants to other entry inhibitors
used, as the difference in IC50 of mutant/WT was always less than
twofold. Remarkably the mutation, N276D conferred a 3 to 13
fold increase of sensitivity to both VRC01 and VRC03. The
exception is VI829 Env containing PV, which is not sensitive to
VRC03 both in WT and mutant form.
Structural Analysis Reveals an Interaction between VRC01
Light Chain and N276-linked Glycan
The presence of a glycan at position 276 was confirmed in
several gp120 structures including as ligands sCD4, PGV04, b12
and VRC01 (Figure 1a) and shown to be proximal to the CD4bs
on gp120. In the case of VRC01 the structural analysis revealed
that VRC01 interacts with the N-acetyl-glucosamine of the N276-
linked glycan through the light chain residues tyrosine 28 and
threonine 30 (Figure 1b). These data show that VRC01 interaction
with gp120 may also involve the recognition of a glycan.
Discussion
Previous analysis, comparing b12 and HJ16 indicated that these
mAb recognize a related, but not identical part of the CD4bs: the
binding of gp120 to solid-phase CD4 was inhibited by both mAb
to a similar extent, but cross-competition between b12 and HJ16
for binding to gp120 showed incomplete heterologous inhibition.
Moreover, the D368R mutation in the heart of the CD4bs, well
known to abrogate binding of b12, didn’t affect HJ16 binding to
gp120. The neutralization spectrum of both mAb was clearly
different and largely complementary: while b12 neutralized most
tier 1 viruses, HJ16 failed against these ‘‘easy-to-neutralize’’
viruses, such as BaL, SF162 and MN, but was active against many
tier 2 viruses. Unfortunately, we failed to characterize the epitope,
using overlapping peptides, which suggested that HJ16 recognizes
a discontinuous (conformational) epitope [7,8].
In order to uncover important attachment sites for HJ16
binding on gp120, we used resistance induction in the CRF02_AG
strain VI1090, shown to be susceptible to HJ16 in multiple
neutralization assays [8]. In all four resistance induction experi-
ments the rare N276D point mutation emerged. The area around
276 includes also N262 and N289 and therefore has been reported
as a possible glycosylation site [21]. We applied site directed
mutagenesis in the VI1090 CFR02_AG env to confirm that this
mutation was responsible for the resistance to HJ16 in VI1090 and
showed in addition that introducing the N276D mutation in
sensitive A and C isolates also induced full resistance to HJ16.
Table 3. Neutralization sensitivity to HJ16 and TriMab of
VI1090 before and after HJ16 resistance induction.
HJ16 TriMaba
VI1090_WTb 0.20c 11.75
0.57 32.01
0.69 27.04
VI1090_sens 1b 0.53 33.63
VI1090_sens 2 1.79 34.02
VI1090_sens 3 1.80 32.97
VI1090_sens 4 0.70 12.48
VI1090_res_1b .200 25.59
VI1090_res_2 .200 9.93
VI1090_res_3 .200 11.93
VI1090_res_4 .200 10.51
aTriMab consists of b12, 2G12 and 2F5.
bVI1090_WT is the original HJ16 sensitive stock used to initiate resistance
induction; VI1090_sens is the WT cultured in parallel to the resistance induction
but without HJ16; VI1090_res is the WT cultured in the presence of HJ16 up to a
final concentration of 187.5 mg/ml.
cIC50 values (mg/ml) in TZMbl assay.
doi:10.1371/journal.pone.0068863.t003
Table 4. Influence of N276D in different Envs on their
sensitivity to various entry inhibitors in TZMbl assay.
Assay VI1090
a 92RW009.6a VI829a
WT N276D WT N276D WT N276D
HJ16 0.085b .200 0.123 .200 48.17 .200
b12 .200 .200 .200 .200 9.68 4.20
A12 .100 .100 .100 .100 .100 .100
1B5 .100 .100 28.71 44.06 6.65 4.57
M48-U1 0.16 0.16 0.50 0.59 0.04 0.02
sCD4 13.81 7.11 39.56 29.60 0.55 0.34
VRC01 0.16 0.03 0.44 0.14 0.90 0.07
VRC03 0.04 ,0.01 2.69 0.3 .50 .50
Maraviroc ,0.01 ,0.01 ,0.01 ,0.01 ,0.01 ,0.01
TriMab 5.76 12.56 16.53 27.65 60.20 28.71
aThe Envs from VI1090 (CRF02_AG), 92RW009.6 (subtype A) and VI829 (subtype
C) were either used as such (WT) or after site-directed mutagenesis at the 276
position to construct PV for the TZMbl assay.
bMean IC50 (mg/ml) of at least two (VRC01 and VRC03) or three (all others)
independent experiments are shown.
doi:10.1371/journal.pone.0068863.t004
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These results could be explained by the fact that the 276 position is
located in the C2 part of the outer domain of gp120, which in the
three-dimensional structure is relatively close to, but yet just
outside the CD4bs [22]. The mutation failed to clearly alter the
sensitivity towards most CD4bs targeting compounds, such as
sCD4, M48-U1 (CD4 miniprotein), CD4bs mAb b12 and the
VHH A12, but intriguingly the sensitivity towards the novel
VRC01 and VRC03 was clearly increased. As could be expected,
the mutation didn’t affect the activity of Maraviroc (CCR5
inhibitor), 1B5 (targeting the CD4i site – submitted for publica-
tion) or TriMab, consisting of 2G12 (recognizing a specific
configuration of glycans, but not including N276, on gp120)
[23,24], 2F5 (recognizing the MPER in gp41) and b12 [1].
Together with our previous findings, the present observations
confirm the uniqueness of this HJ16 mAb that probably blocks the
gp120-CD4 interaction by binding a glycan near the CD4bs.
The importance of glycosylation in binding and activity of HIV-
neutralizing antibodies has recently gained interest. In Lavine’s
study, mutations of subtype B JR-FL and YU-2 viruses at position
234 and 241 (of the inner gp120 domain) as well as 332 and 386
(outer gp120 domain) decreased sensitivity to at least 2 out of 9
broadly neutralizing patient sera. Of these N332S and N386T also
abrogated the neutralizing capacity of mAb 2G12, as could be
expected. Conversely, a number of PNGS in V1 (position 160), V2
(197), V3 (301) and gp41 (616) increased sensitivity to neutrali-
zation by 5 to 9 out of the 9 patient sera. Remarkably the N276S
mutation also increased sensitivity to neutralization by two patient
sera [21]. A second paper by Wang et al. studied the effect of
glycan removal on sensitivity to various neutralizing mAbs and
found that several mutation of PNGS in V4/V5 and C2/C3/C4
regions of gp120 from a Chinese BC strain alter neutralization
sensitivity of these mAbs to a variable extent, but consistently
reduced sensitivity to the glycan specific PG16 [22]. Unfortunately
mutation of 276 was not studied by Wang.
A few years ago, Walker et al. described a series of very broadly
neutralizing PGT mAbs, which recognize the glycans at position
N332 in the C3 region of gp120 [4]. Moore et al. showed that
mutation of N332 abrogates the neutralizing activity of mAb
PGT128 [25], whereas Moldt et al found that the related glycan-
specific mAb PGT121 can protect against infection with
SHIVSF162 [26]. All these findings underline the importance of
PNGS Abs for future vaccine development.
Conversely, the paper by McGuire at al. (which appeared
during the revision of this manuscript) shows enhanced binding of
both the mature and germline reverted version of the potent
CD4bs-specific VRC01 to the 276D mutant subtype C virus
(labeled 266c), which lacks the natural complex glycan as
compared to WT N276 [27]. Available structural data, however,
showed an interaction between VRC01 light chain and the N276-
bound N-acetyl glucosamine. It is important to note that the
gp120 used to make co-crystals are treated with glycosidases (Endo
H in the case of the VRC01 structure which leaves a N-acetyl
glucosamine residue on N276) and that the glycan bound to N276
is most likely of larger size and complexity on the native gp120.
The presence of a bulkier glycan at N276 position may indeed
clash with VRC01 light chain, as confirmed by Jardine et al [28],
thus reducing its overall affinity for the N276 glycosylated gp120
as compared to gp120 lacking this glycan, as already suggested by
McGuire’s data. Our data on increased sensitivity of N276D
mutants of subtype A, C and CRF02 Env towards neutralization
by VRC01 therefore provide an important functional correlate to
McGuire’s and Jardine’s observations and indicate that the
interactions between the N276 glycan and the VRC01 light chain
residues is in fact not a requirement for antibody binding.
Figure 1. Positioning in yellow of N276-bound glycans (yellow spheres) in solved structures for sCD4, PGV04, b12 and VRC01. The
blue highlight indicate the footprint of the cognate ligand and the red spheres the other glycans. A N276 glycan on gp120 structures. In blue are
shown the footprints of CD4 (pdb accession nu 1gc1) and the CD4bs-specific antibodies PGV04 (pdb nu: 3se9), b12 (pdb nu: 3dnl), and VRC01 (pdb nu:
3ngb). In each structure the N276-bound glycan is highlighted in yellow, other, surrounding glycans in red. B. Detail of the molecular interaction
between the residues tyrosine 28 and threonine 30 of the VRC01 light chain with N-acetyl-glucosamine of the N276-bound glycan (3ngb). Figures
were made with PyMOL.
doi:10.1371/journal.pone.0068863.g001
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In conclusion, similar to PG9 and PGT128, binding outside the
CD4bs [22,25] and in contrast to other CD4bs mAb, such as
VRC01, the HJ16 epitope may be constituted of a glyco-peptide.
Whereas McGuire’s data, supplemented with ours on VRC01
suggest that the N276 glycosylation (present in most WT HIV-1)
hinders the recognition and maturation of VRC01-like antibodies
in vivo, this glycan is most probably required for HJ16-like
antibody induction. This knowledge is of obvious interest to
design new Env-specific immunogens for the induction of ‘tier 2-
type’ CD4bs specific neutralizing antibodies.
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